Orrstown Financial Services Inc. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 35.5% during the 4th quarter, Holdings Channel reports. The firm owned 947 shares of the pharmaceutical company’s stock after purchasing an additional 248 shares during the quarter. Orrstown Financial Services Inc.’s holdings in Vertex Pharmaceuticals were worth $381,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Northwest Investment Counselors LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $27,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $35,000. Institutional investors own 90.96% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on VRTX. Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. JPMorgan Chase & Co. lowered their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Canaccord Genuity Group boosted their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research report on Wednesday, November 6th. Finally, Citigroup assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $575.00 price target on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $494.76.
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ VRTX traded down $1.19 during mid-day trading on Wednesday, hitting $439.49. 147,467 shares of the stock traded hands, compared to its average volume of 1,440,316. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a 50 day simple moving average of $434.75 and a two-hundred day simple moving average of $463.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The company has a market cap of $113.18 billion, a PE ratio of -220.70, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the firm posted $3.67 earnings per share. The firm’s revenue was up 11.6% compared to the same quarter last year. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Conference Calls and Individual Investors
- 3 Steel Stocks Soaring After Tariff Announcements
- The Most Important Warren Buffett Stock for Investors: His Own
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- CD Calculator: Certificate of Deposit Calculator
- Why Salesforce Stock Could Be at Fresh Highs by February
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.